anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND OBJECTIVES: The optimal timing between preoperative embolization of hypervascular metastatic bone lesions and surgery has yet to be established. Our analysis sought to evaluate embolization timing impacts blood loss, transfusion risk, and operative time in patients with hypervascular primary tumors.
METHODS: We identified patients with renal cell (RCC) or thyroid carcinoma undergoing surgery between 1992 and 2023. Patients were segregated into the following cohorts: (1) no embolization preoperatively, (2) surgery <24 h of embolization, and (3) surgery >24 h after embolization. Multivariate logistic regression analyses were performed to assess the effect of embolization timing while controlling for confounding variables.
RESULTS: No differences were seen in all evaluated outcomes between immediate and delayed embolization cohorts. No differences in estimated blood loss were seen between the immediate (OR: 0.685, 95% CI: 0.159-2.949; p = 0.611) and delayed (OR: 0.568, 95% CI: 0.093-3.462; p = 0.539) surgery cohorts compared with patients without embolization. Surgery >24 h after embolization was not associated with a higher risk of prolonged operative time (OR: 13.499, 95% CI: 0.832-219.146; p = 0.067).
CONCLUSIONS: These findings suggest that surgery may be safely delayed beyond 24 h from embolization without a higher risk of bleeding. In appropriately selected cohorts, embolization may not be needed preoperatively.
CO2 used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is not standard procedure and therefore experimental intervention.
For the 12-day Titration Phase, rufinamide will be administered orally in doses starting with 400 milligram (mg) twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the 12 week Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
Failure to achieve target-specific delivery to ischemic brain sites has hampered the clinical efficacy of newly developed therapies for ischemic stroke. Emodin, an active ingredient isolated from traditional Chinese medicine, has been indicated to alleviate ischemic stroke; however, the underlying mechanism remains unclear. In this study, we aimed to achieve brain-targeted delivery of emodin to maximize its therapeutic efficacy and elucidate the mechanisms by which emodin alleviates ischemic stroke. A polyethylene glycol (PEG)/cyclic Arg-Gly-Asp (cRGD)-modified liposome was used to encapsulate emodin. TTC, HE, Nissl staining, and immunofluorescence staining were employed to evaluate the therapeutic efficacy of brain-targeting emodin in MCAO and OGD/R models. Inflammatory cytokine levels were determined using ELISA. Immunoprecipitation, immunoblotting, and RT-qPCR were utilized for clarifying the changes in key downstream signaling. Lentivirus-mediated gene restoration was employed to verify the core effector of emodin for relieving ischemic stroke. Encapsulating emodin in a PEG/cRGD-modified liposome enhanced its accumulation in the infarct region and substantially raised its therapeutic efficacy. Furthermore, we demonstrated that AQP4, the most abundant water transporter subunit expressed in astrocytes, plays a crucial role in mediating the mechanisms by which emodin inhibits astrocyte swelling, neuroinflammatory blood-brain barrier (BBB) breakdown in vivo and in vitro, and brain edema in general. Our study unveiled the critical target of emodin responsible for alleviating ischemic stroke and a localizable drug delivery vehicle in the therapeutic strategy for ischemic stroke and other brain injuries.
BACKGROUND: Dysbiosis of gut microbiota is frequent in liver cirrhosis (LC) patients, and splenectomy (SP) has been reported to improve LC. Herein, we report the effects of SP on gut microbiota, especially on Veillonella parvula, a Gram-negative coccus of the gastrointestinal tract, in LC mice, and the underlying mechanism.
METHODS: LC mice models were induced by tail vein injection of concanavalin A (ConA), followed by SP. 16 s rRNA sequencing was conducted to analyze the effects of ConA induction and SP on mouse gut microbiota and the gene expression affected by gut microbiota. LC mice receiving SP were gavaged with Veillonella parvula. Likewise, hepatic stellate cells (HSC) and hepatocytes (HC) were induced with conditioned medium (CM) of Veillonella parvula.
RESULTS: SP alleviated LC in mice by restoring gut barrier function and maintaining gut microbiota balance, with Veillonella as the key genus. The Veillonella parvula gavage on LC mice reversed the ameliorative effect of SP. The CM of Veillonella parvula promoted the activation of HSC and the release of IL-6, IL-1β, and TNF-α. Also, the CM of Veillonella parvula induced HC pyroptosis and the release of ALT and AST. Veillonella parvula represented an imbalance in the gut microbiota, thus enhancing gut-derived endotoxins in the liver with the main target being Tlr4/Nlrp3. Inhibition of Tlr4 blocked Veillonella parvula-induced HC damage, HSC activation, and subsequent LC progression.
CONCLUSION: SP-mediated gut microbiota regulation ameliorates ConA-related LC progression by inhibiting Tlr4/Nlrp3 in the liver.
Myorisan should be administered with a meal (see PRECAUTIONS: Information for Patients).

The recommended dosage range for Myorisan is 0.5 to 1 mg/kg/day given in two divided doses with food for 15 to 20 weeks. In studies comparing 0.1, 0.5, and 1 mg/kg/day,8 it was found that all dosages provided initial clearing of disease, but there was a greater need for retreatment with the lower dosages. During treatment, the dose may be adjusted according to response of the disease and/or the appearance of clinical side effects — some of which may be dose related. Adult patients whose disease is very severe with scarring or is primarily manifested on the trunk may require dose adjustments up to 2 mg/kg/day, as tolerated. Failure to take Myorisan with food will significantly decrease absorption. Before upward dose adjustments are made, the patients should be questioned about their compliance with food instructions.

The safety of once daily dosing with Myorisan has not been established. Once daily dosing is not recommended. 

If the total nodule count has been reduced by more than 70% prior to completing 15 to 20 weeks of treatment, the drug may be discontinued. After a period of 2 months or more off therapy, and if warranted by persistent or recurring severe nodular acne, a second course of therapy may be initiated. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth. Long-term use of Myorisan, even in low doses, has not been studied, and is not recommended. It is important that Myorisan be given at the recommended doses for no longer than the recommended duration. The effect of long-term use of Myorisan on bone loss is unknown (see WARNINGS: Skeletal: Bone Mineral Density, Hyperostosis, and Premature Epiphyseal Closure).

Contraceptive measures must be followed for any subsequent course of therapy (see PRECAUTIONS).
The LHM arm (N=300) will receive a CBT+ Cardiovascular Health (CVH) Intervention to reduce CV risk. LHM employs a cognitive behavioral training (CBT) + cardiovascular health (CVH) intervention delivered by doulas and integrating a healthy lifestyle intervention to reduce CV risk. The LHM intervention integrates the following key elements: (1) doula-led emergency detection in the first 7 days post-discharge; (2) home BP monitoring (HBPM); and (3) 11-sessions of the doula-delivered intervention to prevent PPD and reduce CV risk from 1 week to 6 months post-discharge, supported by (4) education through the Patient-Activated Learning System (PALS), a novel education platform used to engage low-literacy, racially marginalized individuals. LHM is based on the Thinking Healthy Programme (THP), an intervention originally designed to treat PPD in low and middle-income countries using community health workers.
Novel 2-tetrahydrofurfuryl-6,7-benzomorphans of the formula I, in which     R<1> denotes methyl, ethyl or propyl;   R<2> denotes hydrogen, methyl or ethyl;   R<3> denotes hydrogen or methyl; and   R<4> denotes hydrogen or alkyl having 1 to 4 carbon atoms  are prepared by reducing an appropriately quaternised compound. The resulting bases of the formula I can then be converted into their acid addition salts. The compounds of the formula I and their acid addition salts are distinguished by a therapeutically utilisable action on the central nervous system. Particularly to be emphasised is their analgesic action, which frequently excels that of morphine, without exhibiting the undesired side effects of morphine, e.g. the addictive action. <IMAGE>
Glucocorticoids periorbital injection. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
Empirical evidence suggests that body ownership and the sense of agency operate as an interactive system correlated with the level of consciousness during tasks involving modifications in body representation. This study sought to elucidate the nature of this association by documenting the verbal manifestations of this interaction. Specifically, the study aimed to reveal the role of a sense of agency in the individual sensitivity to the Rubber Hand Illusion (RHI). The sense of agency was measured through a post hoc interview wherein participants could verbally express their rubber hand ownership and real hand disownership experiences following the RHI examination. The RHI was induced in 49 healthy, right-handed college volunteers, including 28 males (mean age 28.6) and 21 females (mean age 26.6). Three main scores - ownership, disownership, and proprioceptive drift - were defined to measure individual sensitivity to Rubber Hand Illusion. Verbal reports related to the RHI were analyzed utilizing an automated narrative content analysis toolkit which explored the deeper content of words and stories to identify situation-driven cognitive processes, specifically focusing on the rate of sense of agency and other cognitive variables. The findings indicated that a greater disruption in the sense of agency predicts increased sensitivity to the Rubber Hand Illusion. Therefore, individuals with a lower rate sense of agency exhibit increased malleability in body representation when a rubber hand illusion is induced.
Up to twenty (20) de-identified hepatocellular carcinoma (HCC) tissue sections on biopsy slides or frozen sections and associated information such as age, sex, race, ethnicity, treatment status, pathological diagnoses, and date of procedure will be obtained from UC Davis Cancer Center Biorepository (CCB) and outside tissue biobanks, including, but not limited to, Cooperative Human Tissue Network (CHTN). The duration anticipated to complete analysis and publication is 2 years.
The SH control condition involves two sessions (ACASI assessment and control condition), one at study entry (prior to beginning ART) and one a month later. Then, participants will complete ACASI assessments only at 3, 6, 9, and 12 months. The first SH session targets healthy eating and physical activity and is matched for dose and length of time of the intervention session. Feedback and education are provided, if desired. Finally, the participants may engage in goal setting for healthy eating and physical activity. The second SH session focuses on the goals set during the first session and behavior over the previous month.
In the early years of my GI fellowship, a healthy 40-year-old man came to my clinic and announced that he was going to die of pancreatic cancer. His brothers, father and uncles had all died of the disease; he felt his fate was inescapable. I asked whether his family members had seen doctors or had any tests. His answer was yes to both. Even so, doctors could not diagnose the pancreatic cancer at early stages. CT scans were always negative. I thought to myself, in order to help this patient-CT scans may not be reliable for early detection. Perhaps other methods of imaging the pancreas might be of more benefit. This patient opened a door that led to a 30-year journey of trying to detect pancreatic cancer at earlier stages when it is curable.
PURPOSE: To perform the dyeing of a keratin fiber such as hair in a soft and glossy dyed state by using a composition containing an indole derivative and a specific quinone dye and using iodide ion and hydrogen peroxide, etc., as a color-developing agent. CONSTITUTION: Keratin fiber is treated with a composition containing an indole derivative of the formula I (R1 is H, a lower alkyl, etc.; R2 and R3 are each H, a lower alkyl, etc.; R4 and R5 are each H, a 1-20C alkyl, etc.), its mineral acid salt, etc., and a quinone dye such as 1,4-naphthoquinone of the formula II (R13 is H, a halogen, etc., when R12 is OH; R14 to R17 are each H, hydroxy, etc.) or benzoquinone of the formula III (R18 to R21 are each H, hydroxy, etc.) in a medium suitable for dyeing. The development of the color is performed by using iodide ion and H2 O2 , a nitrite, etc.
Participants in this group received a placebo instead of medication. The placebo was taken once a day on days 1-3, twice a day on days 4-15.
BACKGROUND: Breast cancer is one of the most common malignant tumors in women. Cell division cycle associated 5 (CDCA5), a master regulator of sister chromatid cohesion, was reported to be upregulated in several types of cancer. Here, the function and regulation mechanism of CDCA5 in breast cancer were explored.
METHODS: CDCA5 expression was identified through immunohistochemistry staining in breast cancer specimens. The correlation between CDCA5 expression with clinicopathological features and prognosis of breast cancer patients was analyzed using a tissue microarray. CDCA5 function in breast cancer was explored in CDCA5-overexpressed/knockdown cells and mice models. Co-IP, ChIP and dual-luciferase reporter assay assays were performed to clarify underlying molecular mechanisms.
RESULTS: We found that CDCA5 was expressed at a higher level in breast cancer tissues and cell lines, and overexpression of CDCA5 was significantly associated with poor prognosis of patients with breast cancer. Moreover, CDCA5 knockdown significantly suppressed the proliferation and migration, while promoted apoptosis in vitro. Mechanistically, we revealed that CDCA5 played an important role in promoting the binding of E2F transcription factor 1 (E2F1) to the forkhead box M1 (FOXM1) promoter. Furthermore, the data of in vitro and in vivo revealed that depletion of FOXM1 alleviated the effect of CDCA5 overexpression on breast cancer. Additionally, we revealed that the Wnt/β-catenin signaling pathway was required for CDCA5 induced progression of breast cancer.
CONCLUSIONS: We suggested that CDCA5 promoted progression of breast cancer via CDCA5/FOXM1/Wnt axis, CDCA5 might serve as a novel therapeutic target for breast cancer treatment.
Dosage forms of a pharmaceutical composition comprising a sealed actives compartment containing a stable prostaglandin in a pharmaceutical composition for topical application to a patient are disclosed. Preferably, the prostaglandin compound is substantially uniformly dispersed in a delivery vehicle, and in certain embodiments the prostaglandin compound contains stabilizing agent comprising a moisture scavenger, an antioxidant and a chelating agent for metal ions. In certain embodiments the delivery vehicle is preferably substantially anhydrous, free of metal ions and oxygen and water. The improved compositions of the present invention are useful for treating medical conditions by providing a packed mono or multi-component dosage form that comprises a sealed section containing an active pharmaceutical ingredient and a delivery vehicle pharmaceutically compatible for topical delivery. The medical condition can be, for example male or female sexual dysfunction broadly and male erectile dysfunction specifically. Alternately, the medical condition can be a wound or other conditions such as hemorrhoids. In preferred embodiments of the medical treatment methods the active pharmaceutical ingredient is prostaglandin, and most preferably, the prostaglandin is treated with a stabilizing agent comprising a moisture scavenger, an antioxidant and a chelating agent for metal ions. In a specific application of the foregoing, a sock saturated with a gel forming material acting as lubricant is also disclosed which preferably has at least one wound healing composition to treat a foot skin condition, preferably using a wound healing composition such as prostaglandin.
Heterogeneous extracellular vesicles (EVs) from various types of tumours are acknowledged for inducing the formation of pre-metastatic "niches" in draining lymph nodes (LNs) to promote lymphatic metastasis. In order to identify the specific subpopulations of EVs involved, we performed high-resolution proteomic analysis combined with nanoflow cytometry of bladder cancer (BCa) tissue-derived EVs to identify a novel subset of tumour-derived EVs that contain integrin α6 (ITGA6+EVs) and revealed the positive correlation of ITGA6+EVs with the formation of pre-metastatic niche in draining LNs and lymphatic metastasis in multicentre clinical analysis of 820-case BCa patients. BCa-derived ITGA6+EVs induced E-selectin (SELE)-marked lymphatic remodelling pre-metastatic niche and promoted metastasis in draining LNs through delivering cargo circRNA-LIPAR to lymphatic endothelial cells in vivo and in vitro. Mechanistically, LIPAR linked ITGA6 to the switch II domain of RAB5A and sustained RAB5A GTP-bound activated state, thus maintaining the production of ITGA6+EVs loaded with LIPAR through endosomal trafficking. ITGA6+EVs targeted lymphatic vessels through ITGA6-CD151 interplay and released LIPAR to induce SELE overexpression-marked lymphatic remodelling pre-metastatic niche. Importantly, we constructed engineered-ITGA6 EVs to inhibit lymphatic pre-metastatic niche, which suppressed lymphatic metastasis and prolonged survival in preclinical models. Collectively, our study uncovers the mechanism of BCa-derived ITGA6+EVs mediating pre-metastatic niche and provides an engineered-EV-based strategy against BCa lymphatic metastasis.
Scalp-care preparations contain as active substance at least one uronic acid (pref. glucuronic acid, esp. D-glucuronic acid, or glucuronic acid gamma-lactone) in a carrier material which is pharmaceutically tolerable when applied externally. The concentration of uronic acid in the preparations is pref. 0.1-10 g (esp. 0.5-5 g) per 100 ml carrier material when the carrier material is a liquid. The preparations are useful as cosmetic or therapeutic/prophylactic medicinal agents for application to the scalp. They prevent itching of the scalp and excessive secretion by the scalp sebaceous glands, and diminish dandruff, hair-loss and greying of the hair. The individual hairs are strengthened, hair growth is promoted, and the air takes on a voluminous appearance.
This invention is directed to acylated amino acid amidyl pyrazoles and related compounds of Formula (I). The invention is also directed to a pharmaceutical formation comprising such compound or in a pharmaceutically acceptable salt form thereof. The invention is further directed to a method for inhibiting .beta.-amyloid peptide release and/or synthesis, a method for inhibiting .gamma.--secretase activity, and a method for treating neurological disorders associated with .beta.-amyloid peptide production. The method comprises administering to a host a pharmaceutical formulation comprising an effective amount of a compound of Formula (I). The compounds of Formula (I) are useful in the prevention and treatment of Alzheimer's disease.   (see formula I)
Pregnant women will be individually randomized; a daily dose of vitamin D in 4000 IU will be given to Intervention group, started at 20-22 weeks of pregnancy till the time of delivery. The infants of this group will further stratify into two groups, one group will receive 400 IU of Vitamin D for 6 months as Intervention.
PURPOSE:To obtain a fine powder composition having excellent flowability and handleability, by adding and dispersing microfibrillated cellulose to a medicine, cosmetic or food having high hygroscopicity. CONSTITUTION:The objective easily flowable powdery composition is produced by adding and dispersing microfibrillated cellulose to a highly hygroscopic medicine (e.g. ethambutol, theophylline, etc.), cosmetic or food (e.g. powdery milk, amino acid seasoning, etc.). The powder of a highly hygroscopic medicine, etc., is liable to cause the blocking or deliquescense by moisture absorption when left in air. Crystalline cellulose, etc., is used as an additive to improve the flowability and handleability of the powder, however, it has unagreeable taste and a large amount of the additive is necessary. MFC is a substance similar to crystalline cellulose and having remarkably improved moisture stabil ity and palatability.
The participants will train during 12 weeks with progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, including 2 in closed kinetic chain exercises and 2 executed with the elastic band or with dumbbell/weight. All the exercises will be performed with no/slight pain, ranging between 0 and 2 on NPRS. 10/15 minutes of manual therapy (posterior capsular release) will be applied during the physiotherapy session.